Variant Bio Funding: $130M Raised, Series B (2021)

Variant Bio is based in Brooklyn. It has raised $130M in total funding. Latest round: Series B. Backed by Lux Capital, General Catalyst, Alta Partners.

Variant Bio funding overview

Variant Bio is based in Brooklyn. Variant Bio has raised $130M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in November 2021. The round record for Variant Bio runs through 2021; nothing later has been disclosed. Investors on record include Lux Capital, General Catalyst, Alta Partners, SoftBank, Cercano Management, Casdin Capital and 1 others. 7 distinct backers are named across the disclosed rounds.

Variant Bio at a glance

Total raised
$130M
Latest round
Series B
Latest round date
November 2021
Headquarters
Brooklyn
Notable investors
Lux Capital, General Catalyst, Alta Partners, SoftBank, Cercano Management, Casdin Capital, Sahsen Ventures

Frequently asked about Variant Bio funding

How much has Variant Bio raised?
Variant Bio has raised $130M in total disclosed funding across the rounds on record.
Who has invested in Variant Bio?
Lux Capital, General Catalyst, Alta Partners, SoftBank, Cercano Management, Casdin Capital are named among the investors backing Variant Bio.
What was the latest Variant Bio funding round?
The most recent disclosed round is a Series B, announced in November 2021.
Where is Variant Bio based?
Variant Bio is based in Brooklyn.
When did Variant Bio last raise?
The last disclosed Variant Bio round closed in November 2021 at Series B.

Variant Bio totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Brooklyn below to benchmark round size and investor mix.

Companies related to Variant Bio (36)

Browse related funding lists (7)

Company funding database · Investor directory · Founder database · Mega-rounds 2026